GSK Prevails in Second Zantac Cancer Case to Go to Trial.

LEGAL costs; RANITIDINE; CARCINOGENS; INVESTORS; COLORECTAL cancer

GSK Plc has won a second trial in Illinois, successfully convincing a jury that the former heartburn drug Zantac was not responsible for a woman's colorectal cancer. This follows a similar verdict in Chicago a few months ago. GSK is one of several drugmakers facing lawsuits from individuals who claim that the active ingredient in Zantac, ranitidine, can turn into a potential carcinogen. The US Food and Drug Administration has already requested the removal of all ranitidine-based drugs from the market. GSK still has thousands of cases pending in the US, and while they have settled some cases, they have not admitted liability. The ongoing lawsuits have negatively impacted the company's stock. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)